John Brognard

8PUBLICATIONS

54CO-AUTHORS

Molecular targetsAdversarial machine learningBasic pharmacologyCancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|Jun 02, 2026

Suppression of AKT Activation Through LZK Inhibition Limits Tumor Growth in Esophageal and Head and Neck Cancers.

|May 25, 2026

A first-in-class precision antibody conjugate targeting EGFR, mTOR, and PI3K to treat head and neck cancers.

|Jun 10, 2025

CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor-driven proteome through PARP7 activity.

Andrii Gorelik, Joao A Paulo, Christina B Schroeter

|Feb 11, 2025

Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors.

Amy L Funk, Meghri Katerji, Marwa Afifi

|Aug 16, 2024

Dual inhibition of EGFR and PI3K with a single drug.

Meghri Katerji, Maxine R Rubin, John Brognard

|Jun 10, 2024

TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy.

Triet Nguyen, Francesca A Carrieri, Nick Connis

Pageof 2

Frequent Collaborators

Ivan Ahel

Pedro Torres-Ayuso

Tung Hoang

Amol C Shetty

Shreya Jagtap

Triet Nguyen

Francesca Anna Carrieri

2 joint publications

Nick Connis

2 joint publications

Audrey Lafargue

2 joint publications

Jinhee Chang

Frequent Collaborators

Ivan Ahel

Pedro Torres-Ayuso

Tung Hoang

Amol C Shetty